The Zhitong Finance App noticed that before the market on Tuesday, Novo Nordisk (NVO.US) shares rose 7.5% after the US Food and Drug Administration (FDA) approved its weight loss pills. This gave the company a competitive edge in the rapidly evolving obesity treatment market.

The Zhitong Finance App noticed that before the market on Tuesday, Novo Nordisk (NVO.US) shares rose 7.5% after the US Food and Drug Administration (FDA) approved its weight loss pills. This gave the company a competitive edge in the rapidly evolving obesity treatment market.